Cerulean Pharma Inc. is a clinical-stage oncology-focused company applying its tumor targeting platform. The Company’s nanopharmaceutical product candidates consist of polymers that are linked to anti-cancer therapeutics, or payloads. Its lead product candidate, CRLX101, is in Phase II clinical development and has the potential to address cancer therapies. CRLX301, the second product candidate, is a nanopharmaceutical with docetaxel, a microtubule stabilizer, as its anti-cancer payload. The clinical development of CRLX101 is focused on cancer indications. A two-part Phase II open-label IST of CRLX101 is being conducted in patients with relapsed ovarian cancer. CRLX301 is designed to act as a tubulin inhibitor, capitalizes on its payload, docetaxel.
Address
5th Floor, 840 Memorial Drive
CAMBRIDGE, MA 02139
United States
CAMBRIDGE, MA 02139
United States
Website
http://ceruleanrx.comKey stats and ratios
| Q1 (Mar '14) | 2013 | |
| Net profit margin | -6200.00% | -285716.70% |
| Operating margin | -6293.62% | -264333.30% |
| EBITD margin | - | -261050.00% |
| Return on average assets | -125.13% | -140.01% |
| Return on average equity | - | - |
| Employees | 21 |
No comments:
Post a Comment